<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Nimodipine, <z:chebi fb="0" ids="30353">isopropyl</z:chebi> (2-<z:chebi fb="8" ids="32772">methoxy</z:chebi>-ethyl) 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-<z:chebi fb="0" ids="36173">pyridinedicarboxylate</z:chebi>, is a new calcium antagonistic <z:chebi fb="1" ids="35620">vasodilator</z:chebi> with a preferential effect on brain vessels </plain></SENT>
<SENT sid="1" pm="."><plain>Nimodipine prevents spasm of the isolated rabbit basilar artery produced both by depolarization and by receptor stimulation </plain></SENT>
<SENT sid="2" pm="."><plain>In peripheral vessels nimodipine does not inhibit agonistically induced contractions </plain></SENT>
<SENT sid="3" pm="."><plain>In vivo nimodipine also dilates predominantly cerebral vessels; peripheral vasodilation resulting in a decrease in blood pressure is much less pronounced </plain></SENT>
<SENT sid="4" pm="."><plain>Nimodipine prevents the impaired reperfusion of the brain caused by a transitory global <z:e sem="disease" ids="C0917798" disease_type="Disease or Syndrome" abbrv="">cerebral ischaemia</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Nimodipine is predicted to be useful in the prophylaxis and treatment of <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> in humans </plain></SENT>
</text></document>